German healthcare and life sciences giant Bayer acquiring KaNDy Therapeutics also made a splash, with the buyer paying $425m upfront, up to $450m in development milestone payments and ‘triple-digit millions’ in commercial milestones. The deal was right in the wheelhouse of Goodwin’s vaunted London life sciences practice, with the UK-based biotech KaNDy Therapeutics and its shareholders calling in a team led by Graham Defries for the disposal. Defries pointed to the unusually large scale of the transaction. Read the Legal Business article here.
In The Press August 13, 2020